Yoon, Jennifer A.

Jennifer A. Yoon

Partner

jennifer.yoon@lw.com
    Yoon, Jennifer A.

    Jennifer A. Yoon

    Partner

    jennifer.yoon@lw.com
    "Wonderful to work with, very professional and skilled."

    Chambers USA 2024

    "Simply fantastic. She has the ability to juggle multiple complex workstreams and advise at both a granular and highly sophisticated level."

    Chambers USA 2024

    Up-and-Coming – Corporate/M&A: Capital Markets

    Chambers USA 2024

    "She is excellent and unflappable."

    Chambers USA 2023

    "Jennifer is exceptional. She is confident, poised and has a deep knowledge."

    Chambers USA 2022

    "She is exceptionally talented on the law and a high-quality client service provider."

    Chambers USA 2021

    "She is extremely professional and unflappable."

    Chambers USA 2021

    Profile

    Jennifer A. Yoon advises clients across the life sciences industry on complex corporate and securities law matters.

    Jennifer combines extensive transactional experience and a client-first approach to guide biotechnology and other life sciences companies at every stage of maturity through:

    • Public offerings, including initial public offerings (IPO), follow-on offerings, at-the-market offerings, and private investments in public entities
    • Securities law compliance and public company representation
    • Corporate governance and strategy for early-stage companies
    • Preferred equity financings for early-stage companies

    She keenly understands the capital markets implications for life sciences companies and distills complex scientific and legal jargon into actionable client advice. Jennifer develops trusted, long-term relationships to both help clients navigate high-stakes transactions and strategize solutions to day-to-day corporate issues that arise.

    A recognized leader at the firm, Jennifer serves on the Ethics Committee and previously served on the Associates Committee.

    Before her legal career, Jennifer was a children’s book editor.

    Experience

    Public Offerings and Transactions

    Jennifer's experience includes advising on:

    • Frequency Therapeutics’ US$84 million IPO of its common stock
    • Kiniksa Pharmaceuticals’ US$152 million IPO of its common stock
    • Momenta Pharmaceuticals’ US$230 million follow-on offering of its common stock
    • Verona Pharma’s US$79 million offering of its American depositary shares and other follow-on offerings
    • Merus’ US$61 million IPO of its common shares, as well as its:
      • Offering of 5.462 million shares of common stock
      • Financing of up to US$75 million shares of common stock
      • Offering of 5.575 million shares of common stock
      • US$110 million offering
    • Seres Therapeutics’ US$154 million IPO of its common stock
    • SQZ Biotechnologies’ IPO of its common stock
    • Rapid Micro Biosystems’ IPO of its common stock
    • Rhythm Pharmaceuticals’ 2022 financing
    • Atea Pharmaceuticals’ IPO
    • Omega Therapeutics’ IPO
    • Ayala Pharmaceuticals’ IPO
    • Desktop Metal’s convertible notes offering

    Public Company Representation

    Jennifer's experience representing US and international public companies in their securities law compliance and other public company matters includes advising:

    • Frequency Therapeutics
    • Kiniksa Pharmaceuticals

    Early-Stage Companies

    Jennifer's experience representing early-stage companies in their preferred equity financings and on corporate governance strategy includes advising:

    • Omaha National (check)
    • Oncologie in its Series B convertible preferred share financing

    Qualifications

    Bar Qualification

    • Massachusetts

    Education

    • JD, Northwestern University School of Law, 2013
    • BA, Oberlin College, 2002
      Phi Beta Kappa

    Practices

    Industries

    Recognition

    News & Insights

    Read More